Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.

Iwao T, Sakai K, Sata M

Journal of diabetes and its complications3 Aug 2012Cited by 25 (Europe PMC)

PMID22863615DOI10.1016/j.jdiacomp.2012.07.001PepBankPUB-22863615

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyOther
In Japanese adults with type 2 diabetes switched from insulin to liraglutide monotherapy, duration of disease was significantly higher in unsuccessful than in successful patients.
In plain wordsIn Japanese adults with type 2 diabetes switched from insulin to liraglutide, those with longer disease duration were less likely to switch successfully.
Peptide
Liraglutide
Outcome
Not applicableDisease duration in unsuccessful versus successful switching
Study
n = 69
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Using univariate analysis, duration of disease was significantly higher in unsuccessful patients than in successful patients.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361501
02HumanObservational studyOther
In Japanese adults with type 2 diabetes switched from insulin to liraglutide monotherapy, urinary, fasting and postprandial C-peptide were significantly higher in successful than in unsuccessful patients.
In plain wordsIn Japanese adults with type 2 diabetes switched from insulin to liraglutide, higher C-peptide before switching was linked to a successful switch.
Peptide
Liraglutide
Outcome
Not applicableC-peptide levels in successful versus unsuccessful switching
Study
n = 69
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Urinary C-peptide, fasting C-peptide, and postprandial C-peptides were significantly higher in successful patients than in unsuccessful patients.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361502
03HumanObservational studyOther
In Japanese adults with type 2 diabetes, postprandial C-peptide at 60 min was an independent predictor of successful switching from insulin to liraglutide monotherapy (odds ratio 7.28).
In plain wordsIn Japanese adults with type 2 diabetes, C-peptide measured 60 minutes after a meal predicted a successful switch from insulin to liraglutide.
Peptide
Liraglutide
Outcome
Not applicablePostprandial C-peptide at 60 min as predictor of successful switching
Study
n = 69
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Odds ratio
7.28
postprandial C-peptide at 60 min
95% CI
2.89 to 18.36
odds ratio
Source sentences
Summary
Multiple logistic regression analysis showed that postprandial C-peptide at 60 min was an independent predictor of successful switching to liraglutide monotherapy from insulin therapy (odds ratio, 7.28; 95% confidence interval, 2.89-18.36).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361503
04HumanObservational studyOther
In Japanese adults with type 2 diabetes, a postprandial C-peptide cut-off of 2.9 ng/mL at 60 min predicted successful switching to liraglutide with sensitivity 95% and specificity 93%.
In plain wordsIn Japanese adults with type 2 diabetes, a C-peptide level of 2.9 ng/mL, 60 minutes after a meal, predicted a successful switch to liraglutide well.
Peptide
Liraglutide
Outcome
Not applicableBest cut-off of postprandial C-peptide at 60 min
Study
n = 69
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Cut-off
2.9 ng/mL
postprandial C-peptide at 60 min
Sensitivity
95%
cut-off 2.9 ng/mL
Specificity
93%
cut-off 2.9 ng/mL
Source sentences
Summary
In the receiver operating characteristic analyses, 2.9 ng/mL of postprandial C-peptide at 60 min was the best cut-off value, providing that sensitivity and specificity were 95% and 93%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361504
05HumanObservational studyEfficacy outcome
In Japanese adults with type 2 diabetes successfully switched from insulin to liraglutide monotherapy, HbA1c showed a sustained reduction during follow-up.
In plain wordsIn Japanese adults with type 2 diabetes who switched successfully from insulin to liraglutide, HbA1c stayed lower during follow-up.
Peptide
Liraglutide
Outcome
DecreaseHbA1c after switching to liraglutide
Study
n = 39
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In the follow-up period, successful patients showed a sustained reduction in HbA(1c) and body weight without hypoglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
In successful patients, HbA(1c) and body weight were measured at 4, 8, and 12 weeks after switching.
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361505
06HumanObservational studyEfficacy outcome
In Japanese adults with type 2 diabetes successfully switched from insulin to liraglutide monotherapy, body weight showed a sustained reduction during follow-up.
In plain wordsIn Japanese adults with type 2 diabetes who switched successfully from insulin to liraglutide, body weight stayed lower during follow-up.
Peptide
Liraglutide
Outcome
DecreaseBody weight after switching to liraglutide
Study
n = 39
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In the follow-up period, successful patients showed a sustained reduction in HbA(1c) and body weight without hypoglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
In successful patients, HbA(1c) and body weight were measured at 4, 8, and 12 weeks after switching.
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361506
07HumanObservational studySafety outcome
In Japanese adults with type 2 diabetes successfully switched from insulin to liraglutide monotherapy, the reductions occurred without hypoglycemia.
In plain wordsIn Japanese adults with type 2 diabetes who switched successfully from insulin to liraglutide, no low blood sugar was reported during follow-up.
Peptide
Liraglutide
Outcome
No significant changeHypoglycemia after switching to liraglutide
Study
n = 39
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In the follow-up period, successful patients showed a sustained reduction in HbA(1c) and body weight without hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 69 patients with type 2 diabetes, including 39 consecutive successful patients and 30 consecutive unsuccessful patients from insulin therapy to liraglutide monotherapy.
Report a problemFND-2286361507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.